Articles

The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL). Read More ›

An interim analysis from the informCLL Real-World Registry found that most ibrutinib-treated patients started at the FDA-recommended once-daily dose of 420 mg, with few dose interruptions or reductions over time. Read More ›

The combination of ibrutinib and CTL119, an anti-CD19 CAR T-cell antibody, showed promising results in a pilot trial with ibrutinib, with a high rate of patients achieving minimal residual disease–negative status. Read More ›

Researchers report promising findings for patients treated with a venetoclax-rituximab combination regimen in relapsed/refractory chronic lymphocytic leukemia (CLL). Read More ›

New data suggest that adding obinutuzumab to ibrutinib in patients with chronic lymphocytic leukemia (CLL) may be effective at improving minimal residual disease (MRD) response rates, especially in patients with low tumor burden after prior ibrutinib therapy. Read More ›

Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial. Read More ›

Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support. Read More ›

The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile. Read More ›

Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer. Read More ›

Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens. Read More ›